Transparency, Power, and Influence in the Pharmaceutical Industry: Policy Gain or Confidence Game?

Edited by Katherine Fierlbeck, Janice Graham, and Matthew Herder

© 2021

There is plenty of controversy surrounding pharmaceuticals, but it cannot be denied that it is both a socially beneficial and profit-making industry. Regulators are expected to ensure that the economic success of the pharmaceutical industry does not come at the expense of public safety, yet regulators have also assumed a cooperative role by providing advice on regulation and by targeting unmet medical needs. Concerns over regulatory standards, conflicts of interest, and the manipulation of information on drug safety and effectiveness have led to public mistrust and a greater need for transparency between pharmaceutical industry and government regulators.

Transparency, Power, and Influence in the Pharmaceutical Industry evaluates the progress made in holding the pharmaceutical industry responsible for creating transparency in the industry, from development to market. The contributors to this volume examine the various mechanisms introduced to make the regulatory process more informative and situate these efforts within the larger project of enhancing the safety of drugs, vaccines, and other products.

Continue Reading Read Less

Product Details

  • World Rights
  • Page Count: 304 pages
  • Dimensions: 6.0in x 1.0in x 9.0in
Product Formats

SaveUP TO 9239

Book Formats

SKU# SP006685

  • AVAILABLE JUL 2021

    From: $26.96

    Regular Price: $35.95

    ISBN 9781487529048
  • AVAILABLE AUG 2021

    From: $60.00

    Regular Price: $80.00

    ISBN 9781487529031
  • AVAILABLE AUG 2021

    From: $26.96

    Regular Price: $35.95

Quick Overview

Transparency, Power, and Influence in the Pharmaceutical Industry evaluates the progress made in holding the pharmaceutical industry to account through greater transparency.

Transparency, Power, and Influence in the Pharmaceutical Industry: Policy Gain or Confidence Game?

Edited by Katherine Fierlbeck, Janice Graham, and Matthew Herder

© 2021

There is plenty of controversy surrounding pharmaceuticals, but it cannot be denied that it is both a socially beneficial and profit-making industry. Regulators are expected to ensure that the economic success of the pharmaceutical industry does not come at the expense of public safety, yet regulators have also assumed a cooperative role by providing advice on regulation and by targeting unmet medical needs. Concerns over regulatory standards, conflicts of interest, and the manipulation of information on drug safety and effectiveness have led to public mistrust and a greater need for transparency between pharmaceutical industry and government regulators.

Transparency, Power, and Influence in the Pharmaceutical Industry evaluates the progress made in holding the pharmaceutical industry responsible for creating transparency in the industry, from development to market. The contributors to this volume examine the various mechanisms introduced to make the regulatory process more informative and situate these efforts within the larger project of enhancing the safety of drugs, vaccines, and other products.

Continue Reading Read Less

Product Details

  • World Rights
  • Page Count: 304 pages
  • Dimensions: 6.0in x 1.0in x 9.0in
  • Author Information

    Katherine Fierlbeck is the McCulloch Professor of Political Science at Dalhousie University, with a cross-appointment as professor of Community Health and Epidemiology.


    Janice Graham is a professor of Paediatrics (infectious diseases) and Medical Anthropology, and the University Research Professor at Dalhousie University.


    Matthew Herder is the director of the Health Law Institute and an associate professor of Medicine and Law at Dalhousie University.
  • Table of contents

    1. Introduction
    Katherine Fierlbeck, Janice Graham, and Matthew Herder

    2. Transparency, Pharmaceuticals, and the Problem of Policy Change
    Katherine Fierlbeck

    3. Data Transparency and Pharmaceutical Regulation in Europe: Road to Damascus, or Room without a View?
    Courtney Davis, Shai Mulinari, and Tom Jefferson

    4. FDA and Health Canada: Similar Origins, yet Divergent Paths and Approaches to Transparency
    Margaret McCarthy and Joe Ross

    5. Clinical Trial Data Transparency in Canada: Mapping the Progress from Laggard to Leader
    Marc-André Gagnon, Matthew Herder, Janice Graham, Katherine Fierlbeck, and Anna Danyliuk

    6. How Clinical Study Information Transparency Can Fail to Serve Its Purpose, and How the Essential Medicines Concept Can Help
    Nav Persaud

    7. Speak No Secrets: (Non)transparency in Health Canada’s Communications about Pharmaceutical Regulation
    Joel Lexchin

    8. Economic Ghost-Management in the Pharmaceutical Sector
    Marc-Andre Gagnon

    9. Balancing the Privacy Rights of Research Participants with the Public Interest in Clinical Drug Trials Data in the Context of Rare Diseases
    Kanksha Mahadevia Ghimire and Trudo Lemmens

    10. The European Registration of the Pandemic Influenza Vaccine Pandemrix: A Case Study of the Consequences of Poor Clinical Data Transparency
    Tom Jefferson

    11. Sharing Data and Ideas for Good Health: How Researchers Can Sustain an Ethical and Transparent Health System
    Rita Banzi

    12. Conclusion
    Katherine Fierlbeck, Janice Graham, and Matthew Herder

By the Same Author(s)

Related Titles